+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Evaluation of first-trimester screening by fetal nuchal translucency and maternal age



Evaluation of first-trimester screening by fetal nuchal translucency and maternal age



Prenatal Diagnosis 18(2): 133-137



The aim of this screening study was to evaluate first-trimester screening for chromosomal defects by fetal nuchal translucency thickness at 10-14 weeks of gestation in four Fetal Medicine Units in Greece. Estimates of the risk for trisomy 21 were calculated taking into account fetal nuchal translucency thickness and maternal age. There were 3550 cases; the median maternal age was 29 years (range 16-48 years); and 277 (7.8 per cent) were over 37 years. The median crown rump length was 60 mm (range 38-85 mm) and the fetal nuchal translucency thickness increased with crown rump length and measurements were above the 95th centile in 101 (2.9 per cent) of the cases. The adjusted risk was 1 in 300 or more in 172 (4.9 per cent) of the cases and the high-risk group contained ten of the 11 (91 per cent) fetuses with trisomy 21 and all 11 fetuses with other chromosomal defects. The findings of this study provide further evidence for the high efficacy of screening for chromosomal abnormalities by fetal nuchal translucency and maternal age.

(PDF emailed within 0-6 h: $19.90)

Accession: 046009848

Download citation: RISBibTeXText

PMID: 9516014

DOI: 10.1002/(sici)1097-0223(199802)18:2<133::aid-pd236>3.0.co;2-o


Related references

Comparison and integration of first trimester fetal nuchal translucency and second trimester maternal serum screening for fetal Down syndrome. Prenatal Diagnosis 22(8): 730-735, 2002

Screening for fetal trisomy 21 in the first trimester of pregnancy: maternal serum free beta-hCG and fetal nuchal translucency thickness. Ultrasound in Obstetrics & Gynecology 6(6): 390-395, 1995

UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 352(9125): 343-346, 1998

First trimester screening for Down's syndrome using maternal serum PAPP-A and free beta-hCG in combination with fetal nuchal translucency thickness. British Journal of Obstetrics and Gynaecology 105(8): 917-920, 1998

A re-evaluation of the influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy. Prenatal Diagnosis 30(10): 937-940, 2011

First-trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell-free DNA testing. Ultrasound in Obstetrics & Gynecology 45(1): 42-47, 2015

Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening. Journal of the Formosan Medical Association 100(5): 319-325, 2001

Accuracy of Down syndrome risks produced in a first-trimester screening programme incorporating fetal nuchal translucency thickness and maternal serum biochemistry. Prenatal Diagnosis 22(3): 244-246, 2002

Age related detection and false positive rates when screening for Down's syndrome in the first trimester using fetal nuchal translucency and maternal serum free betahCG and PAPP-A. Bjog 108(10): 1043-1046, 2001

The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy. Prenatal Diagnosis 24(3): 169-173, 2004

Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome. Ultrasound in Obstetrics & Gynecology 10(4): 261-264, 1997

Low molecular weight heparin and first trimester maternal PAPP-A and hCG levels, fetal nuchal translucency in the first trimester of pregnancy. Clinical and Experimental Obstetrics & Gynecology 38(1): 81-83, 2011

Prospective evaluation of a first trimester screening program for Down syndrome and other chromosomal abnormalities using maternal age, nuchal translucency and biochemistry in an Australian population. Australian & New Zealand Journal of Obstetrics & Gynaecology 44(3): 205-209, 2004

First trimester ultrasound screening for Down syndrome based on maternal age, fetal nuchal translucency and different combinations of the additional markers nasal bone, tricuspid and ductus venosus flow. Prenatal Diagnosis 35(12): 1182-1186, 2016

Sequential screening for trisomy 21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a low-risk population. Ultrasound in Obstetrics & Gynecology 18(1): 23-25, 2001